Section 4.4:
Elderly patients are particularly liable to lithium toxicity.
Caution in patients with cardiovascular disease or family history of QT prolongation.
Avoid concomitant antipsychotics.
Caution is advised in patients with cardiovascular disease or family history of QT prolongation.
Concomitant administration of antipsychotics should be avoided.
Section 4.5
Interactions may occur with concomitant QT interval prolonging drugs.
Interactions may occur with drugs which cause electrolyte imbalance.
Use with concomitant QT prolonging drugs (e.g. Class IA and III antiarrhythmics, arsenic trioxide, dolasetron mesylate, mefloquine, IV erythromycin) is not recommended.
Use with drugs causing electrolyte imbalance is not recommended.
Section 4.8
Exacerbation of psoriasis may occur.
Cardiovascular effects of lithium are rare and often benign. Reported effects are ventricular arrhythmia, ventricular fibrillation, ventricular tachycardia (rare), oedema, and sinus node dysfunction. Any signs of cardiac disturbance e.g. syncope, heart rhythm or rate disturbances should be investigated further. QT interval prolongation, sudden unexplained death, cardiac arrest, Torsade de pointes.
Cardiovascular effects of lithium are rare and often benign. Reported effects are arrhythmia, oedema and sinus node dysfunction. QT interval prolongation, ventricular arrhythmias – ventricular fibrillation, ventricular tachycardia (rare), sudden unexplained death, cardiac arrest and Torsade de pointes have been reported, Any signs of cardiac disturbance e.g. syncope, heart rhythm or rate disturbances should be investigated further.
Section 10:
Date approved: 28 September 2006
|
